MetLife Investment Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $42.6M | Sell |
85,023
-2,798
| -3% | -$1.34M | 0.19% | 70 |
|
|
2026
Q1 | $43.2M | Sell |
87,821
-2,279
| -3% | -$1.24M | 0.22% | 62 |
|
|
2025
Q4 | $52.2M | Sell |
90,100
-3,594
| -4% | -$2.03M | 0.25% | 49 |
|
|
2025
Q3 | $45.4M | Sell |
93,694
-2,497
| -3% | -$1.16M | 0.22% | 64 |
|
|
2025
Q2 | $39M | Sell |
96,191
-3,149
| -3% | -$1.32M | 0.23% | 63 |
|
|
2025
Q1 | $49.4M | Sell |
99,340
-1,894
| -2% | -$1.03M | 0.27% | 52 |
|
|
2024
Q4 | $52.7M | Buy |
101,234
+1,901
| +2% | +$1.05M | 0.29% | 46 |
|
|
2024
Q3 | $61.4M | Sell |
99,333
-2,489
| -2% | -$1.47M | 0.35% | 35 |
|
|
2024
Q2 | $56.3M | Buy |
101,822
+1,533
| +2% | +$878K | 0.33% | 38 |
|
|
2024
Q1 | $58.3M | Sell |
100,289
-3,293
| -3% | -$1.85M | 0.39% | 35 |
|
|
2023
Q4 | $55M | Sell |
103,582
-1,786
| -2% | -$864K | 0.4% | 35 |
|
|
2023
Q3 | $53.3M | Sell |
105,368
-2,443
| -2% | -$1.3M | 0.42% | 33 |
|
|
2023
Q2 | $56.3M | Buy |
107,811
+4,704
| +5% | +$2.54M | 0.41% | 33 |
|
|
2023
Q1 | $59.4M | Sell |
103,107
-1,209
| -1% | -$681K | 0.43% | 29 |
|
|
2022
Q4 | $57.4M | Sell |
104,316
-1,657
| -2% | -$878K | 0.44% | 31 |
|
|
2022
Q3 | $53.7M | Sell |
105,973
-1,444
| -1% | -$808K | 0.45% | 31 |
|
|
2022
Q2 | $58.4M | Sell |
107,417
-1,366
| -1% | -$752K | 0.45% | 32 |
|
|
2022
Q1 | $64.3M | Buy |
108,783
+21,721
| +25% | +$12.5M | 0.42% | 34 |
|
|
2021
Q4 | $58.1M | Sell |
87,062
-1,797
| -2% | -$1.12M | 0.48% | 28 |
|
|
2021
Q3 | $50.8M | Sell |
88,859
-2,263
| -2% | -$1.24M | 0.46% | 30 |
|
|
2021
Q2 | $46M | Sell |
91,122
-2,719
| -3% | -$1.28M | 0.4% | 38 |
|
|
2021
Q1 | $42.8M | Sell |
93,841
-2,412
| -3% | -$1.15M | 0.39% | 40 |
|
|
2020
Q4 | $44.8M | Sell |
96,253
-4,047
| -4% | -$1.9M | 0.42% | 37 |
|
|
2020
Q3 | $44.3M | Sell |
100,300
-2,995
| -3% | -$1.24M | 0.49% | 33 |
|
|
2020
Q2 | $37.4M | Sell |
103,295
-66
| -0.1% | -$22.1K | 0.43% | 39 |
|
|
2020
Q1 | $29.3M | Sell |
103,361
-3,162
| -3% | -$997K | 0.4% | 45 |
|
|
2019
Q4 | $34.6M | Sell |
106,523
-2,461
| -2% | -$746K | 0.36% | 48 |
|
|
2019
Q3 | $31.7M | Sell |
108,984
-1,267
| -1% | -$363K | 0.35% | 52 |
|
|
2019
Q2 | $32.4M | Sell |
110,251
-4,185
| -4% | -$1.15M | 0.35% | 50 |
|
|
2019
Q1 | $31.3M | Sell |
114,436
-692
| -0.6% | -$172K | 0.34% | 55 |
|
|
2018
Q4 | $25.8M | Sell |
115,128
-2,046
| -2% | -$480K | 0.31% | 60 |
|
|
2018
Q3 | $28.6M | Sell |
117,174
-1,261
| -1% | -$290K | 0.29% | 65 |
|
|
2018
Q2 | $24.5M | Sell |
118,435
-2,478
| -2% | -$526K | 0.29% | 57 |
|
|
2018
Q1 | $25M | Sell |
120,913
-3,158
| -3% | -$663K | 0.29% | 60 |
|
|
2017
Q4 | $23.6M | Buy |
+124,071
| New | +$23.8M | 0.27% | 67 |
|
Other funds holding TMO
MetLife Investment Management's TMO Position: Q2 2026 in Review
MetLife Investment Management reduced its Thermo Fisher Scientific (TMO) stake by 3.2% in Q2 2026, selling an estimated $1.34M and leaving 85,023 shares worth $42.6M. The position accounts for 0.19% of the portfolio, ranked #70.
MetLife Investment Management first reported a position in TMO in Q4 2017 and has held it in 35 quarters since. The position peaked at $64.3M in Q1 2022. 2,602 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- MetLife Investment Management held 85,023 shares of Thermo Fisher Scientific worth $42.6M as of Q2 2026.
- MetLife Investment Management sold 2,798 Thermo Fisher Scientific shares in Q2 2026, an estimated $1.34M.
- Thermo Fisher Scientific made up 0.19% of MetLife Investment Management's portfolio in Q2 2026, its #70 holding.
- MetLife Investment Management first reported a position in Thermo Fisher Scientific in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Thermo Fisher Scientific position peaked at $64.3M in Q1 2022.
- 2,602 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.